Previous 10 | Next 10 |
HAMPTON, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody platfor...
HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor conferences in November: Guggenheim 3 rd Annual Healthcare Talks Neuro/Immunology Confer...
Celldex (NASDAQ:CLDX): Q3 GAAP EPS of -$0.45 misses by $0.09. Revenue of $0.15M (-77.6% Y/Y) misses by $1.07M. Press Release For further details see: Celldex EPS misses by $0.09, misses on revenue
HAMPTON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. “During the third quarter we reported compelling data from our ongoing Phas...
The smaller cap biotech space offers two key advantages for investors right now: cyclical diversification and diversification away from the vaccine monolithic theme. To break that down a bit, the stock market has been volatile over the past month, with many growth plays getting smacked down a...
A resistance line and a level of support has formed in the chart of Celldex Therapeutics Inc. (CLDX). At some point, the stock is expected to break through the resistance. When that occurs, a breakout is expected. Read more to learn how to profit from this trade. Celldex Therapeutics Inc....
- Rapid and sustained improvement in urticaria control after single dose of CDX-0159 - - Greatly improved patient quality of life and reduced disease impact - - Data further support 95% complete response rate to provocation testing - HAMPTON, N.J., Sept. 29, 2021 (GLOBE ...
HAMPTON, N.J., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 1:20 p.m. ET. A webcast of ...
21st Century advances on 20th century genetic technologies have opened Celldex Therapeutics Inc.’s developments aimed specifically at induced weaknesses. At this point of the market they also outdo the prospects of many stocks widely-held by Seeking Alpha readers, contributors,...
HAMPTON, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing symptom control and quality of life measurements from the Phase 1b study of CDX-0159 in patients with antihistamine refractory cold contact urticaria (ColdU...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...